Zevra Homepage.
icon news News icon investors Investors icon careers Careers icon contact Contacts

PUBLICATIONS AND PRESENTATIONS

Poster Presentations - 2025 to 2024
Sleep Europe - 09/27/2024

Safety and Efficacy of KP1077 in a Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Patients with Idiopathic Hypersomnia
Read More
Sleep Europe - 09/26/2024

Safety and Efficacy of KP1077 in a Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Patients with Idiopathic Hypersomnia
Read More
SLEEP 2024 Annual Meeting - 06/03/2024

Safety and Efficacy of KP1077 in a Phase 2, Double-blind, Randomized Trial in Patients With Idiopathic Hypersomnia
Read More
SLEEP 2024 Annual Meeting - 06/03/2024

Pharmacokinetics of Morning and Nighttime Doses of KP1077, an Investigational Treatment for Idiopathic Hypersomnia
Read More
Beyond Sleepy 2024 Annual Meeting - 06/01/2024

A Novel Investigational Treatment for Hypersomnia: Where We Are and Where We Need to Go
Read More
Filter & Sort
Pipeline Products
Approved Product Literature for Medical Professionals
About Us
Our Mission & Vision The Zevra Story Leadership Board of Directors What We Do Partnering
Patients & Caregiver
Clinical Trials Expanded Access Policy Niemann-Pick Disease Type C Urea Cycle Disorders Vascular Ehlers-Danlos Sleep Disorders
Our Products
MIPLYFFA® OLPRUVA® AZSTARYS®
Our Pipeline
Pipeline Clinical Trials Publications & Presentations Medical Literature Medical Information Investigator-Initiated Studies
Careers
Culture Job Openings
Investors
Investor Relations Events & Presentations Stock Quote & Chart Press Releases Corporate Governance SEC Filings Contact Email Alerts
Contact [email protected] 888.958.1253
Footer link Zevra Facebook
Footer link Zevra X twitter
Footer link Zevra linkedin
© 2026 Zevra Therapeutics.
All rights reserved.
|
 Privacy Policy
|
 Notice at Collection
|
 Your Privacy Choices
|
 Terms of Use